QQQ   307.84 (+1.40%)
AAPL   153.82 (+1.38%)
MSFT   266.54 (+3.80%)
META   190.84 (+2.57%)
GOOGL   106.56 (+3.56%)
AMZN   100.63 (-1.52%)
TSLA   194.07 (-0.35%)
NVDA   218.58 (+3.65%)
NIO   10.77 (-1.46%)
BABA   104.86 (-0.56%)
AMD   84.82 (+1.36%)
T   19.26 (-1.63%)
F   13.36 (+1.67%)
MU   61.67 (+2.82%)
CGC   2.78 (-5.76%)
GE   81.49 (-1.04%)
DIS   110.96 (+0.99%)
AMC   6.09 (-10.44%)
PFE   43.41 (-0.80%)
PYPL   82.63 (+0.36%)
NFLX   359.99 (-0.41%)
QQQ   307.84 (+1.40%)
AAPL   153.82 (+1.38%)
MSFT   266.54 (+3.80%)
META   190.84 (+2.57%)
GOOGL   106.56 (+3.56%)
AMZN   100.63 (-1.52%)
TSLA   194.07 (-0.35%)
NVDA   218.58 (+3.65%)
NIO   10.77 (-1.46%)
BABA   104.86 (-0.56%)
AMD   84.82 (+1.36%)
T   19.26 (-1.63%)
F   13.36 (+1.67%)
MU   61.67 (+2.82%)
CGC   2.78 (-5.76%)
GE   81.49 (-1.04%)
DIS   110.96 (+0.99%)
AMC   6.09 (-10.44%)
PFE   43.41 (-0.80%)
PYPL   82.63 (+0.36%)
NFLX   359.99 (-0.41%)
QQQ   307.84 (+1.40%)
AAPL   153.82 (+1.38%)
MSFT   266.54 (+3.80%)
META   190.84 (+2.57%)
GOOGL   106.56 (+3.56%)
AMZN   100.63 (-1.52%)
TSLA   194.07 (-0.35%)
NVDA   218.58 (+3.65%)
NIO   10.77 (-1.46%)
BABA   104.86 (-0.56%)
AMD   84.82 (+1.36%)
T   19.26 (-1.63%)
F   13.36 (+1.67%)
MU   61.67 (+2.82%)
CGC   2.78 (-5.76%)
GE   81.49 (-1.04%)
DIS   110.96 (+0.99%)
AMC   6.09 (-10.44%)
PFE   43.41 (-0.80%)
PYPL   82.63 (+0.36%)
NFLX   359.99 (-0.41%)
QQQ   307.84 (+1.40%)
AAPL   153.82 (+1.38%)
MSFT   266.54 (+3.80%)
META   190.84 (+2.57%)
GOOGL   106.56 (+3.56%)
AMZN   100.63 (-1.52%)
TSLA   194.07 (-0.35%)
NVDA   218.58 (+3.65%)
NIO   10.77 (-1.46%)
BABA   104.86 (-0.56%)
AMD   84.82 (+1.36%)
T   19.26 (-1.63%)
F   13.36 (+1.67%)
MU   61.67 (+2.82%)
CGC   2.78 (-5.76%)
GE   81.49 (-1.04%)
DIS   110.96 (+0.99%)
AMC   6.09 (-10.44%)
PFE   43.41 (-0.80%)
PYPL   82.63 (+0.36%)
NFLX   359.99 (-0.41%)
NASDAQ:REPL

Replimune Group - REPL Stock Forecast, Price & News

$28.45
+0.29 (+1.03%)
(As of 02/7/2023 03:25 PM ET)
Add
Compare
Today's Range
$27.92
▼
$28.86
50-Day Range
$18.89
▼
$29.09
52-Week Range
$13.05
▼
$29.52
Volume
97,044 shs
Average Volume
390,002 shs
Market Capitalization
$1.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.57

Replimune Group MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
81.7% Upside
$51.57 Price Target
Short Interest
Bearish
5.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.28
Upright™ Environmental Score
News Sentiment
0.00mentions of Replimune Group in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$375,450 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.99) to ($3.23) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

449th out of 1,029 stocks

Biological Products, Except Diagnostic Industry

70th out of 168 stocks

See Top Rated MarketRank™ Stocks Here
REPL stock logo

About Replimune Group (NASDAQ:REPL) Stock

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin A. Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

REPL Stock News Headlines

February 7, 2023 | finance.yahoo.com
Replimune to Present at the Virtual SVB Securities Global Biopharma Conference
February 3, 2023 | americanbankingnews.com
Head-To-Head Analysis: Replimune Group (NASDAQ:REPL) vs. bluebird bio (NASDAQ:BLUE)
February 7, 2023 | Investing Trends (Ad)
Apple, Amazon, and Walmart are Investing in Solar Energy
The global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.
January 6, 2023 | finance.yahoo.com
Recent Price Trend in Replimune Group, Inc. (REPL) is Your Friend, Here's Why
January 6, 2023 | finance.yahoo.com
Institutional investors may adopt severe steps after Replimune Group, Inc.'s (NASDAQ:REPL) latest 5.3% drop adds to a year losses
January 6, 2023 | finance.yahoo.com
Wall Street Analysts Think Replimune Group, Inc. (REPL) Could Surge 87.88%: Read This Before Placing a Bet
January 4, 2023 | it.tmcnet.com
Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer
January 3, 2023 | finance.yahoo.com
Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference
February 7, 2023 | Investing Trends (Ad)
Apple, Amazon, and Walmart are Investing in Solar Energy
The global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.
December 14, 2022 | finance.yahoo.com
Replimune Breaks Out: Could Rise 30% From Here
December 12, 2022 | finance.yahoo.com
Analyst Beefs Up Replimune Price Target As Recent Data Validates Treatment Platform
December 7, 2022 | marketwatch.com
Replimune Shares Rally on Pipeline Advances >REPL
December 7, 2022 | finance.yahoo.com
Replimune Shares Surge After Early Data From Pretreated Melanoma Patients
December 7, 2022 | marketwatch.com
Replimune, Roche to Develop RP3 in Colorectal Cancer, Hepatocellular Carcinoma >REPL
December 7, 2022 | seekingalpha.com
Replimune in pact with Roche to study cancer drug combos
December 7, 2022 | finance.yahoo.com
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma
December 7, 2022 | finance.yahoo.com
Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update
November 23, 2022 | finance.yahoo.com
Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022 | finance.yahoo.com
Replimune to Host Virtual Investor Event on December 7, 2022
November 3, 2022 | finanznachrichten.de
Replimune Group Inc: Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
October 15, 2022 | finance.yahoo.com
Replimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The Catalysts
October 14, 2022 | markets.businessinsider.com
Expert Ratings for Replimune Group
August 24, 2022 | finance.yahoo.com
Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks
August 12, 2022 | seekingalpha.com
Replimune: Recent Developments Strengthen Bull Thesis
August 6, 2022 | finance.yahoo.com
Is Replimune Group (NASDAQ:REPL) Using Too Much Debt?
July 17, 2022 | uk.finance.yahoo.com
Replimune Group, Inc. (REPL)
June 3, 2022 | finance.yahoo.com
Replimune Announces the Departure of Jason Rhodes from its Board of Directors
See More Headlines
Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

REPL Company Calendar

Last Earnings
11/04/2021
Today
2/07/2023
Next Earnings (Estimated)
2/09/2023
Fiscal Year End
3/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:REPL
CUSIP
N/A
CIK
1737953
Web
www.replimune.com
Phone
(781) 222-9600
Fax
N/A
Employees
152
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$51.57
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+81.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.74)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-118,040,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-35.72%
Return on Assets
-31.86%

Debt

Debt-to-Equity Ratio
0.06
Current Ratio
16.12
Quick Ratio
16.12

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.71 per share
Price / Book
3.27

Miscellaneous

Outstanding Shares
49,740,000
Free Float
37,901,000
Market Cap
$1.42 billion
Optionable
Not Optionable
Beta
1.65

Key Executives

  • Philip Astley-Sparke
    Chief Executive Officer & Director
  • Robert CoffinRobert Coffin
    President & Director
  • Colin A. LoveColin A. Love
    Chief Operating Officer
  • Jean M. Franchi
    Chief Financial Officer, Secretary & Treasurer
  • Pamela EspositoPamela Esposito
    Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













REPL Stock - Frequently Asked Questions

Should I buy or sell Replimune Group stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" REPL shares.
View REPL analyst ratings or view top-rated stocks.

What is Replimune Group's stock price forecast for 2023?

7 brokerages have issued twelve-month target prices for Replimune Group's shares. Their REPL share price forecasts range from $34.00 to $70.00. On average, they predict the company's share price to reach $51.57 in the next twelve months. This suggests a possible upside of 81.5% from the stock's current price.
View analysts price targets for REPL or view top-rated stocks among Wall Street analysts.

How have REPL shares performed in 2023?

Replimune Group's stock was trading at $27.20 at the beginning of the year. Since then, REPL shares have increased by 4.5% and is now trading at $28.42.
View the best growth stocks for 2023 here.

When is Replimune Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our REPL earnings forecast.

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.05.

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

When did Replimune Group IPO?

(REPL) raised $100 million in an IPO on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is Replimune Group's stock symbol?

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Who are Replimune Group's major shareholders?

Replimune Group's stock is owned by a variety of retail and institutional investors. Top institutional investors include Emerald Advisers LLC (2.38%), Frazier Life Sciences Management L.P. (1.87%), TD Asset Management Inc (0.27%), Moody Aldrich Partners LLC (0.18%), Fisher Asset Management LLC (0.14%) and Hennion & Walsh Asset Management Inc. (0.07%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke and Robert Coffin.
View institutional ownership trends.

How do I buy shares of Replimune Group?

Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Replimune Group's stock price today?

One share of REPL stock can currently be purchased for approximately $28.42.

How much money does Replimune Group make?

Replimune Group (NASDAQ:REPL) has a market capitalization of $1.41 billion. The company earns $-118,040,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis.

How many employees does Replimune Group have?

The company employs 152 workers across the globe.

How can I contact Replimune Group?

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The official website for the company is www.replimune.com. The company can be reached via phone at (781) 222-9600 or via email at ir@replimune.com.

This page (NASDAQ:REPL) was last updated on 2/7/2023 by MarketBeat.com Staff